Bioanalysis of bevacizumab and infliximab by high-temperature reversed-phase liquid chromatography with fluorescence detection after immunoaffinity magnetic purification

Todoroki, Kenichiro; Nakano, Tatsuki; Eda, Yasuhiro; Ohyama, Kaname; Hayashi, Hideki; Tsuji, Daiki; Min, Jun Zhe; Inoue, Kōichi; Iwamoto, Naoki; Kawakami, Atsushi; Ueki, Yukitaka; Itoh, Ken; Toyo’oka, Toshimasa

doi:10.1016/j.aca.2016.02.029

Cited by 28 publications

(27 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of them are able to measure both IFX and antibodies to IFX, whereas others are specific for one of these quantifications. Most of the available methods rely on an Enzyme‐Linked Immunosorbent Assay (ELISA) technique, whereas alternative ones, based on, for instance, immunoaffinity magnetic purification coupled with high‐temperature reversed‐phase liquid chromatography, fluid‐phase radioimmunoassays (RIA), reporter gene assays and liquid chromatography linked with mass spectrometry are becoming increasingly acknowledged …”

Section: Introductionmentioning

confidence: 99%

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays

Afonso

Lopes²,

Gonçalves

et al. 2016

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARY BackgroundTherapeutic drug monitoring is a powerful strategy known to improve the clinical outcomes and to optimise the healthcare resources in the treatment of autoimmune diseases. Currently, most of the methods commercially available for the quantification of infliximab (IFX) are ELISA-based, with a turnaround time of approximately 8 h, and delaying the target dosage adjustment to the following infusion.

show abstract

Section: Introductionmentioning

confidence: 99%

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays

Afonso

Lopes²,

Gonçalves

et al. 2016

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Our group improved this method and reported the bioanalytical methods for bevacizumab and infliximab. 65 Our methods improved especially the pretreatment process of blood samples compared with the previous report, and by using immunoaffinity magnetic beads, it was possible to achieve both an improvement in accuracy and an increase in sensitivity due to increased recovery rates. The proposed methods could be successfully applied to the clinical samples obtained from patients suffering from cancer and rheumatoid arthritis, after being treated with each drug.…”

Section: Bioanalysis Of Therapeutic Mabs and Adcs As Use Of Intact Prmentioning

confidence: 74%

Current Mass Spectrometric Tools for the Bioanalyses of Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugates

et al. 2018

Self Cite

View full text Add to dashboard Cite

The increase in the use of therapeutic monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) has made the detailed bioanalysis of these drugs essential not only for planning optimal therapeutic programs for clinical practice, but also for evaluating the biological equivalencies in the development of other biosimilars. The ligand binding assays that are widely in use now are being replaced rapidly by the highly accurate, sensitive, and selective analytical method using a mass spectrometer. This review will discuss the progress in and challenges observed during the development of a mass spectrometry-based bioanalytical method for therapeutic mAbs and ADCs.

show abstract

“…The analysis of macromolecules, such as bDMARDs by HPLC is difficult. Therefore, appropriate pretreatment and suitable conditions of chromatography are necessary to measure bDMARDs in blood . In this study, we developed an assay using HPLC with a fluorescence detection method for TCZ, after it undergoes a simple and rapid pretreatment.…”

Section: Introductionmentioning

confidence: 99%

Simple and rapid analysis of tocilizumab using HPLC‐fluorescence detection method

et al. 2019

View full text Add to dashboard Cite

We developed a novel assay using high‐performance liquid chromatography (HPLC) with fluorescence detection for the determination of tocilizumab (TCZ), after it has undergone a facile and rapid pretreatment. TCZ belongs to the same subclass as IgG1 (Immunoglobulin G subclass 1), and we could separate TCZ from IgG1 without antigen–antibody reactions, with the novel detection method. The separation of these antibodies was achieved by pretreatment with an organic solvent containing a base, such as trimethylamine and triethylamine. The effect of these bases on the separation of TCZ is related to the hydrophobicity of the base rather than the electrostatic charge. The results indicated that the surface charge of antibodies changed because of the structural change, even though the difference in the amino acid sequences of the antibodies was very low. Our method is available for the separation of the antibody subclasses, and it would be useful to assay TCZ in blood.

show abstract

Bioanalysis of bevacizumab and infliximab by high-temperature reversed-phase liquid chromatography with fluorescence detection after immunoaffinity magnetic purification

Cited by 28 publications

References 34 publications

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays

Current Mass Spectrometric Tools for the Bioanalyses of Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugates

Simple and rapid analysis of tocilizumab using HPLC‐fluorescence detection method

Contact Info

Product

Resources

About